HomeSOBI ⢠STO
add
Swedish Orphan Biovitrum AB (publ)
Previous close
krĀ 285.20
Day range
krĀ 280.20 - krĀ 286.40
Year range
krĀ 241.80 - krĀ 354.40
Market cap
101.60B SEK
Avg Volume
328.85K
P/E ratio
25.00
Dividend yield
-
Primary exchange
STO
In the news
Financials
Income Statement
Revenue
Net income
(SEK) | Mar 2025info | Y/Y change |
---|---|---|
Revenue | 6.46B | 3.34% |
Operating expense | 3.52B | 7.71% |
Net income | 875.00M | 9.38% |
Net profit margin | 13.53 | 5.79% |
Earnings per share | 2.72 | 1.87% |
EBITDA | 2.39B | 0.42% |
Effective tax rate | 20.16% | ā |
Balance Sheet
Total assets
Total liabilities
(SEK) | Mar 2025info | Y/Y change |
---|---|---|
Cash and short-term investments | 997.00M | 89.18% |
Total assets | 70.12B | -5.90% |
Total liabilities | 31.08B | -19.51% |
Total equity | 39.04B | ā |
Shares outstanding | 343.46M | ā |
Price to book | 2.51 | ā |
Return on assets | 4.98% | ā |
Return on capital | 6.58% | ā |
Cash Flow
Net change in cash
(SEK) | Mar 2025info | Y/Y change |
---|---|---|
Net income | 875.00M | 9.38% |
Cash from operations | 2.30B | 1.73% |
Cash from investing | -94.00M | 87.38% |
Cash from financing | -2.29B | -22.95% |
Net change in cash | -143.00M | 62.07% |
Free cash flow | 2.38B | 2,297.81% |
About
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees. Wikipedia
Founded
1939
Website
Employees
1,895